{"pub": "reuters", "url": "https://in.reuters.com/article/uk-astrazeneca-study/astrazeneca-merck-ovarian-cancer-treatment-improves-progression-free-survival-idINKBN1WF0LF", "downloaded_at": "2019-09-30 10:53:27.207832+00:00", "title": "AstraZeneca, Merck ovarian cancer treatment improves progression-free survival", "language": "en", "text": "FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo\n\n(Reuters) - AstraZeneca Plc (AZN.L) and Merck & Co Inc (MRK.N) said on Monday their treatment for newly diagnosed advanced ovarian\n\ncancer improved progression-free survival in patients tested in a late-stage study.\n\nThe study tested Lynparza in patients as an add-on to an already existing standard of care, bevacizumab, and was compared to a group of patients given bevacizumab alone. [nRSd0503Oa]\n\nThe treatment showed a statistically significant and clinically meaningful improvement in progression-free survival in women with newly diagnosed advanced ovarian cancer, the companies said.\n\nLynparza added to bevacizumab reduced the risk of disease progression or death by 41% in the overall trial population.\n\nThe combination also improved progression-free survival to a median of 22.1 months compared to 16.6 months for those treated with bevacizumab alone, the companies said.\n\nThe treatment, which is being jointly developed and commercialized by AstraZeneca and Merck, is approved for the treatment of advanced ovarian cancer and metastatic breast cancer and has been used to treat over 25,000 patients worldwide.\n\nThe American Cancer Society expects about 22,530 women to be newly diagnosed with ovarian cancer in 2019.", "description": "AstraZeneca Plc and Merck & Co Inc said on Monday their treatment for newly diagnosed advanced ovarian", "authors": ["Reuters Editorial", "Min Read"], "top_image": "https://s3.reutersmedia.net/resources/r/?m=02&d=20190930&t=2&i=1435469495&w=1200&r=LYNXMPEF8T0HK", "published_at": "2019-09-30"}